2 Results for "

hepatic lipogenesis disorder

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "hepatic lipogenesis disorder" in MCE Product Catalog:

Cat. No.: HY-182014
CAS No.: 2408041-54-1
Target:  

LXR

TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .
loading...
    loading...
Cat. No.: HY-181117
CAS No.: 86886-76-2
Target:  

YTHDF

Research Areas:  

Cancer

YTH-IN-2 is a YTH domain inhibitor of YTHDC2 with an IC50 of 16.84 μM. YTH-IN-2 can serve as a lead compound for discovering efficient, selective, and cell-active small-molecule inhibitors of YTHDC2.
loading...
    loading...